Oric Pharmaceuticals (ORIC) AI Stock Analysis

• Market Cap: $553.30M
• Dividend Yield: N/A
• Average Volume (3M): 1.29M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.04
• Revenue Growth: N/A
• EPS Growth: 7.15%
• Country: US
• Employees: 115
• Sector: Healthcare
• Sector Strength: 77
• Industry: Biotechnology
• EPS (TTM): -1.83
• Shares Outstanding: 71,026,825
• 10 Day Avg. Volume: 505,902
• 30 Day Avg. Volume: 1,288,946
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -4.90
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $18.50
• Price Target Upside: 137.48% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

Oric Pharmaceuticals scores low overall due to its development stage characteristics, including no revenue generation and negative cash flows. While the company shows strong financial resilience with substantial cash reserves and no debt, its technical indicators signal weakness. Recent corporate events suggest strategic growth, but the lack of positive valuation metrics remains a significant concern.

Positive Factors

Clinical Development

The initiation of pivotal Phase 3 trials for ORIC-944 and ORIC-114 is expected in 2026, indicating progress in the clinical development of these drugs.

Financial Stability

ORIC's cash runway now extends into 2027, providing financial stability and supporting continued development efforts.

Negative Factors

Clinical Development Risks

Risks include potential inability to advance ORIC-114 and ORIC-944 in clinical development and delays in moving into pivotal trials.

Oric Pharmaceuticals Business Overview & Revenue Model

Company Description

Oric Pharmaceuticals (ORIC) is a biopharmaceutical company focused on discovering and developing innovative treatments for cancer. The company operates primarily in the biotechnology sector, leveraging its expertise in oncology to address mechanisms of therapeutic resistance. Its core products are centered around developing small molecule drugs designed to counteract resistance in cancer treatments, thereby improving the efficacy of existing therapies and extending patient survival rates.

How the Company Makes Money

Oric Pharmaceuticals generates revenue primarily through the development and commercialization of its drug candidates. The company seeks to monetize its pipeline by advancing its proprietary compounds through clinical trials and obtaining regulatory approval, which then allows it to either market these drugs directly or license them to larger pharmaceutical companies. Key revenue streams include potential milestone payments, royalties from partnerships with larger pharmaceutical companies, and future product sales upon successful drug approval. Oric may also engage in strategic collaborations and partnerships to co-develop or out-license its technologies, which can provide upfront payments and shared development costs, contributing to its revenue.

Oric Pharmaceuticals Financial Statement Overview

Summary

Oric Pharmaceuticals shows typical characteristics of a biotechnology firm in the development stage, with no revenue generation, negative profitability metrics, and reliance on equity and financing to fund operations. While the balance sheet demonstrates financial stability through high equity and cash reserves, the lack of revenue and ongoing cash consumption present significant risks.

Income Statement

Oric Pharmaceuticals has consistently reported zero revenue over the years, indicating that the company is still in the development phase typical for biotechnology firms. The persistent net losses and negative EBIT and EBITDA highlight ongoing operational challenges without any revenue to offset costs. This results in minimal profitability and growth metrics.

Balance Sheet

The company maintains a strong equity position with zero total debt, resulting in a favorable debt-to-equity ratio. The high equity ratio indicates financial stability, while the substantial cash reserves suggest good liquidity to support ongoing operations and development activities. However, the continuous net losses may eventually impact equity if no revenue generation occurs.

Cash Flow

Operating cash flows have been consistently negative, reflecting the company's cash consumption due to ongoing operations without revenue inflows. The company has managed to maintain liquidity through financing activities, as seen in positive financing cash flows. However, free cash flow remains negative, highlighting the need for continual financing to sustain operations.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	-1.03M	-966.00K	-897.00K	-970.00K
	EBIT
-142.90M	-110.78M	-91.77M	-78.87M	-74.19M
	EBITDA
-142.90M	-109.75M	-91.77M	-77.97M	-74.19M
	Net Income Common Stockholders
-127.85M	-100.70M	-91.48M	-77.68M	-97.27M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
255.96M	208.19M	206.27M	236.98M	293.60M
	Total Assets
274.14M	252.01M	247.18M	298.64M	299.00M
	Total Debt
3.18M	10.21M	2.66M	1.93M	0.00
	Net Debt
-59.41M	-13.17M	-64.18M	-224.08M	-78.45M
	Total Liabilities
31.02M	27.92M	24.83M	25.67M	9.22M
	Stockholders Equity
243.12M	224.09M	222.35M	272.98M	289.78M
Cash Flow		Free Cash Flow
-112.66M	-86.54M	-77.22M	-60.48M	-45.94M
	Operating Cash Flow
-112.66M	-85.69M	-75.14M	-59.54M	-45.27M
	Investing Cash Flow
22.14M	-43.40M	-109.25M	158.44M	-215.96M
	Financing Cash Flow
126.55M	85.66M	25.62M	49.13M	250.51M

Oric Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.79
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORIC, the sentiment is Negative. The current price of 7.79 is below the 20-day moving average (MA) of 7.85, below the 50-day MA of 9.14, and below the 200-day MA of 9.26, indicating a bearish trend. The MACD of -0.44 indicates Negative momentum. The RSI at 43.08 is Neutral, neither overbought nor oversold. The STOCH value of 66.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ORIC.

Oric Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KRYS	77 Outperform	$5.14B	59.36	10.34%	―	473.02%	1620.44%
ZLAB	59 Neutral	$3.85B	―	-31.41%	―	49.59%	24.92%
REPL	53 Neutral	$897.61M	―	-50.50%	―	―	4.28%
Sector *	49 Neutral	$6.87B	0.03	-54.93%	2.50%	24.65%	-2.90%
ADAP	44 Neutral	$115.22M	―	-53.54%	―	145.37%	57.01%
ORIC	42 Neutral	$553.30M	―	-54.73%	―	―	7.15%
FATE	42 Neutral	$107.89M	―	-54.21%	―	-78.55%	-0.92%

Oric Pharmaceuticals Corporate Events

Oric Pharmaceuticals Expands Equity Incentive Plan for Growth

On March 11, 2025, Oric Pharmaceuticals’ Board of Directors approved an amendment to the 2022 Inducement Equity Incentive Plan, increasing the shares reserved for issuance by 1,100,000, totaling 2,250,000 shares. This move, made without stockholder approval under Nasdaq rules, aims to attract new employees and facilitate mergers or acquisitions, aligning with the company’s strategic growth and talent acquisition objectives.

Oric Pharmaceuticals to Present at J.P. Morgan Conference

ORIC Pharmaceuticals plans to present an updated corporate presentation at the J.P. Morgan Healthcare Conference, highlighting its progress in advancing two lead programs, ORIC-114 and ORIC-944, towards pivotal studies. With a strong financial position, the company is well-positioned to continue its development pipeline, targeting new investigational new drug candidates and anticipating significant data milestones in the upcoming years, which could strengthen its industry positioning and impact stakeholders by addressing unmet needs in cancer treatment.